GALENA BIOPHARMA, INC. (NASDAQ:GALE) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07
Submission of Matters to a Vote of Security Holders.
GALENA BIOPHARMA, INC. (NASDAQ:GALE) Files An 8-K Submission of Matters to a Vote of Security Holders
Special Meeting of Stockholders
A special meeting of stockholders of Galena Biopharma, Inc. (“Galena” or “our”) was held on July 6, 2017 (the “Special Meeting”). At the Special Meeting, our stockholders acted upon the following proposals, which are described in detail in our definitive proxy statement filed with the Securities and Exchange Commission on June 9, 2017:
|
Proposal 1: To ratify the filing and effectiveness of the certificate of amendment to our amended and restated certificate of incorporation (as amended) (our “Certificate of Incorporation”) filed with the Secretary of State of the State of Delaware (the “Secretary of State”) on July 26, 2011 and the increase in the number of shares of authorized common stock effected thereby (the “2011 Share Increase Amendment Ratification”). |
|
Proposal 2: To ratify the filing and effectiveness of the certificate of amendment to our Certificate of Incorporation filed with the Secretary of State on June 28, 2013 and the increase in the number of shares of authorized common stock effected thereby (the “2013 Share Increase Amendment Ratification”). |
|
Proposal 3: To ratify the filing and effectiveness of the certificate of amendment to our Certificate of Incorporation filed with the Secretary of State on June 19, 2015 and the increase in the number of shares of authorized common stock effected thereby (the “2015 Share Increase Amendment Ratification”). |
|
Proposal 4: To ratify the filing and effectiveness of the certificate of amendment to our Certificate of Incorporation filed with the Secretary of State on October 17, 2016 and the increase in the number of shares of authorized common stock effected thereby (the “2016 Share Increase Amendment Ratification” and, together with the 2011 Share Increase Amendment Ratification, the 2013 Share Increase Amendment Ratification and the 2015 Share Increase Amendment Ratification, the “Share Increase Amendment Ratifications”). |
|
Proposal 5: To ratify the filing and effectiveness of the certificate of amendment to our Certificate of Incorporation filed with the Secretary of State on November 2, 2016 and the 1-for-20 reverse stock split effected thereby (“Reverse Stock Split Amendment Ratification” and, together with the Share Increase Amendment Ratifications, the “Ratifications”). |
|
Proposal 6: To approve an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of any of the Ratifications. |
Voting Results
Proposal 1: This proposal was approved with 20,051,072 votes “FOR,” 5,138,287 votes “AGAINST,” and 301,637 votes to “ABSTAIN.”
Proposal 2: This proposal was approved with 19,907,881 votes “FOR,” 5,260,890 votes “AGAINST,” and 322,225 votes to “ABSTAIN.”
Proposal 3: This proposal was approved with 19,821,312 votes “FOR,” 5,352,429 votes “AGAINST,” and 317,255 votes to “ABSTAIN.”
Proposal 4: This proposal was approved with 19,802,570 votes “FOR,” 5,360,215 votes “AGAINST,” and 328,211 votes to “ABSTAIN.”
Proposal 5: This proposal was approved with 19,769,037 votes “FOR,” 5,522,855 votes “AGAINST,” and 199,104 votes to “ABSTAIN.”
Proposal 6: This proposal was approved with 18,026,944 votes “FOR,” 5,274,968 votes “AGAINST,” and 2,189,084 votes to “ABSTAIN.”
There were no broker non-votes with respect to any of the proposals.
About GALENA BIOPHARMA, INC. (NASDAQ:GALE)
Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company’s NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company’s therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient’s own immune system to seek out and attack any residual cancer cells.